Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

SELLAS Life Sciences Group Inc. (SLS)

2.42   0.02 (0.83%) 09-29 10:39
Open: 2.44 Pre. Close: 2.4
High: 2.45 Low: 2.42
Volume: 17,175 Market Cap: 23M
SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.533 - 2.547 2.547 - 2.56
Low: 2.368 - 2.383 2.383 - 2.397
Close: 2.378 - 2.403 2.403 - 2.425

Technical analysis

as of: 2020-09-29 10:16:04 AM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 3.40     One year: 3.97
Support: Support1: 2.20    Support2: 1.76
Resistance: Resistance1: 2.91    Resistance2: 3.40
Pivot: 2.31
Moving Average: MA(5): 2.45     MA(20): 2.22
MA(100): 2.93     MA(250): 3.35
MACD: MACD(12,26): -0.01     Signal(9): -0.08
Stochastic oscillator: %K(14,3): 60.46     %D(3): 61.85
RSI: RSI(14): 51.54
52-week: High: 11.00  Low: 1.46  Change(%): -59.2
Average Vol(K): 3-Month: 22162  10-Days: 18739

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
SLS has closed below upper band by 35.5%. Bollinger Bands are 3.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Sun, 13 Sep 2020
SELLAS Life Sciences Group, Inc - Consensus Indicates Potential 310.3% Upside - DirectorsTalk Interviews

Wed, 09 Sep 2020
SELLAS Receives IMPD Approval from the French Regulatory Authority for its Pivotal Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute Myeloid Leukemia - GlobeNewswire

Wed, 09 Sep 2020
SELLAS Life Sciences (SLS) Receives IMPD Approval from French Regulatory Authority for its Pivotal Phase 3 REGAL Study of Galinpepimut-S in Patients with AML - StreetInsider.com

Wed, 02 Sep 2020
Where Does Wall Street Think Sellas Life Sciences Group Inc (SLS) Stock Will Go? - InvestorsObserver

Thu, 13 Aug 2020
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2020 Financial Results - GlobeNewswire

Fri, 31 Jul 2020
SELLAS Life Sciences Announces $9.2 Million Private Placement Priced At-The-Market - GlobeNewswire

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 9
Shares Float (M) 8
% Held by Insiders 2.08
% Held by Institutions 14.53
Shares Short (K) 148
Shares Short P. Month (K) 197

Stock Financials

EPS -4.954
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 0.560
Profit Margin
Operating Margin
Return on Assets (ttm) -54.2
Return on Equity (ttm) -222.8
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth
Operating Cash Flow (M) -18
Levered Free Cash Flow (M) -12

Stock Valuations

PE Ratio -0.49
PEG Ratio
Price to Book value 4.38
Price to Sales
Price to Cash Flow -1.27

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.